The role of the class II transactivator (CIITA) in MHC class I and II regulation and graft rejection in kidney

被引:11
|
作者
Sims, TN
Afrouzian, M
Urmson, J
Zhu, LF
Halloran, PF [1 ]
机构
[1] Univ Alberta, Dept Med Microbiol & Immunol, Heritage Med Res Ctr 250, Edmonton, AB T6G 2S2, Canada
[2] Univ Alberta, Dept Med, Div Nephrol & Immunol, Heritage Med Res Ctr 250, Edmonton, AB T6G 2S2, Canada
[3] Univ Alberta, Dept Lab Med & Pathol, Heritage Med Res Ctr 250, Edmonton, AB T6G 2S2, Canada
[4] Univ Alberta, Dept Surg, Heritage Med Res Ctr 250, Edmonton, AB T6G 2S2, Canada
关键词
antigen presentation; Banff schema; CIITA; graft rejection; MHC regulation;
D O I
10.1034/j.1600-6143.2001.001003211.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Class II transactivator (CIITA) induces transcription of MHC class II genes, and induces class I in some cell lines. We examined the effect of CIITA deficiency on class I and II expression in mouse kidney. In CIITA knockout (CIITAKO) mice, basal class II was absent, but class I levels were mildly but significantly increased. Allogeneic stimulation or ischemic injury increased class I and II expression in kidneys of control (wild-type, WT) mice but induced only class I in CII-TAKO mice. Thus, in kidney, all basal and induced class II expression was CIITA-dependent, but neither basal nor induced class I was CIITA-dependent. Rejecting kidney allografts from CIITAKO mice in CBA hosts manifested intense induction of donor class I but no donor class II expression. Rejecting kidneys from both WT and CIITAKO donors showed predominantly CD8 T-cell infiltration at days 7 and 21, with increasing tubulitis and arteritis at day 21. CIITAKO kidneys showed fewer infiltrating cells than WT kidneys at day 21. Thus CIITA-deficient kidneys have no basal and induced class II expression but display intense induction of class I expression, and evoke typical rejection lesions, although some indices of infiltration are reduced at day 21.
引用
收藏
页码:211 / 221
页数:11
相关论文
共 50 条
  • [21] REGULATION OF MHC CLASS-II EXPRESSION BY INTERFERON-GAMMA MEDIATED BY THE TRANSACTIVATOR GENE CIITA
    STEIMLE, V
    SIEGRIST, CA
    MOTTET, A
    LISOWSKAGROSPIERRE, B
    MACH, B
    SCIENCE, 1994, 265 (5168) : 106 - 109
  • [22] Up-regulation of MHC class II transactivator (CIITA) expression in B lymphocytes by IFN-γ
    Piskurich, JF
    Gilbert, CA
    Ashley, BD
    Wu, J
    Wright, KL
    FASEB JOURNAL, 2003, 17 (07): : C98 - C98
  • [23] The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells
    Barbaro, AD
    Procopio, FA
    Mortara, L
    Tosi, G
    Accolla, RS
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (02) : 603 - 611
  • [24] A possible role of interferon consensus sequence binding protein (ICSBP) in regulating MHC class II expression through class II transactivator (CIITA).
    Konig, S
    Schmidt, M
    Alfken, J
    Hoppe, G
    Nagel, S
    Horak, I
    Levi, BZ
    Neubauer, A
    Wittig, B
    BLOOD, 1997, 90 (10) : 3445 - 3445
  • [25] MHC Class II Transactivator (CIITA) Abnormalities Are Frequent in B-cell Lineage Lymphomas and Are Associated With Loss of MHC Class II (MHCII)
    Jelloul, Fatima Zahra
    Pichardo, Janine D.
    Khattar, Pallavi
    Ananthamurthy, Anuradha
    Rao, Mamta
    Areeyqur, Ruth
    Jungbluth, Achim
    Wang, Lu
    Zhang, Yanming
    Dogan, Ahmet
    MODERN PATHOLOGY, 2018, 31 : 525 - 525
  • [26] Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA
    Virginia Quan
    Michael Towey
    Steven Sacks
    A.P. Kelly
    Immunogenetics, 1999, 49 : 957 - 963
  • [27] Control of tumor growth in vivo by gene therapy with the MHC class II transactivator CIITA
    Meazza, R
    Comes, A
    Barbaro, AD
    Tosi, G
    Ferrini, S
    Accolla, R
    TISSUE ANTIGENS, 2002, 59 : 5 - 5
  • [28] MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
    Christian Steidl
    Sohrab P. Shah
    Bruce W. Woolcock
    Lixin Rui
    Masahiro Kawahara
    Pedro Farinha
    Nathalie A. Johnson
    Yongjun Zhao
    Adele Telenius
    Susana Ben Neriah
    Andrew McPherson
    Barbara Meissner
    Ujunwa C. Okoye
    Arjan Diepstra
    Anke van den Berg
    Mark Sun
    Gillian Leung
    Steven J. Jones
    Joseph M. Connors
    David G. Huntsman
    Kerry J. Savage
    Lisa M. Rimsza
    Douglas E. Horsman
    Louis M. Staudt
    Ulrich Steidl
    Marco A. Marra
    Randy D. Gascoyne
    Nature, 2011, 471 : 377 - 381
  • [29] MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
    Steidl, Christian
    Shah, Sohrab P.
    Woolcock, Bruce W.
    Rui, Lixin
    Kawahara, Masahiro
    Farinha, Pedro
    Johnson, Nathalie A.
    Zhao, Yongjun
    Telenius, Adele
    Ben Neriah, Susana
    McPherson, Andrew
    Meissner, Barbara
    Okoye, Ujunwa C.
    Diepstra, Arjan
    van den Berg, Anke
    Sun, Mark
    Leung, Gillian
    Jones, Steven J.
    Connors, Joseph M.
    Huntsman, David G.
    Savage, Kerry J.
    Rimsza, Lisa M.
    Horsman, Douglas E.
    Staudt, Louis M.
    Steidl, Ulrich
    Marra, Marco A.
    Gascoyne, Randy D.
    NATURE, 2011, 471 (7338) : 377 - +
  • [30] Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA
    Quan, V
    Towey, M
    Sacks, S
    Kelly, AP
    IMMUNOGENETICS, 1999, 49 (11-12) : 957 - 963